Do intravenous and subcutaneous angiotensin II increase blood pressure by different mechanisms?

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 8, 2013, Pages 560-570

  Campbell, Duncan J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Blood pressure; Hypertension; Intravenous; Pressor mechanisms; Subcutaneous

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; MATRIX METALLOPROTEINASE;

ADRENERGIC SYSTEM; ANOREXIA; BLOOD PRESSURE REGULATION; DERMATITIS; DIURESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME INHIBITION; GENETIC MODEL; HEART DISEASE; HUMAN; IMMUNE RESPONSE; KIDNEY DISEASE; KIDNEY MASS; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NONHUMAN; OSMOTIC MINIPUMP; PRESSOR RESPONSE; REVIEW; SEX DIFFERENCE; SKIN FIBROSIS; SKIN NECROSIS; SODIUM EXCRETION; VASOCONSTRICTION; WEIGHT REDUCTION;

EID: 84880998099     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12085     Document Type: Review

References (113)

1. Prieto-Carrasquero MC, Botros FT, Kobori H, Navar LG. Collecting duct renin: A major player in angiotensin II-dependent hypertension. J. Am. Soc. Hypertens. 2009; 3: 96-104.
2. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl Acad. Sci. USA 2006; 103: 17985-90.
3. Guzik TJ, Hoch NE, Brown KA et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007; 204: 2449-60.
4. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008; 29: 367-74.
5. Harrison DG, Guzik TJ, Lob HE et al. Inflammation, immunity, and hypertension. Hypertension 2011; 57: 132-40.
6. McCubbin JW, DeMoura RS, Page IH, Olmsted F. Arterial hypertension elicited by subpressor amounts of angiotensin. Science 1965; 149: 1394-5.
7. Dickinson CJ, Yu R. Mechanisms involved in the progressive pressor response to very small amounts of angiotensin in conscious rabbits. Circ. Res. 1967; 20/21(Suppl. II): II-157-63.
8. Lohmeier TE, Cowley AW Jr. Hypertensive and renal effects of chronic low level intrarenal angiotensin infusion in the dog. Circ. Res. 1979; 44: 154-60.
9. Textor SC, Brunner HR, Gavras H. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension 1981; 3: 269-76.
10. Brown AJ, Casals-Stenzel J, Gofford S, Lever AF, Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am. J. Physiol. 1981; 241: H381-8.
11. Hu L, Catanzaro DF, Pitarresi TM, Laragh JH, Sealey JE. Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats. J. Hypertens. 1998; 16: 1285-98.
12. Campbell WB, Brooks SN, Pettinger WA. Angiotensin II- and angiotensin III-induced aldosterone release in vivo in the rat. Science 1974; 184: 994-6.
13. Duggan J, Nussberger J, Kilfeather S, O'Malley K. Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous angiotensin II. Am. J. Hypertens. 1993; 6: 641-7.
14. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999; 55: 278-85.
15. Vuagnat A, Giacche M, Hopkins PN et al. Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J. Mol. Med. 2001; 79: 175-83.
16. Luther JM, Gainer JV, Murphey LJ et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48: 1050-7.
17. Davern PJ, Head GA. Fos-related antigen immunoreactivity after acute and chronic angiotensin II-induced hypertension in the rabbit brain. Hypertension 2007; 49: 1170-7.
18. Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, Denton KM. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension 2008; 52: 666-71.
19. Simon G, Illyes G, Csiky B. Structural vascular changes in hypertension. Role of angiotensin II, dietary sodium supplementation, blood pressure, and time. Hypertension 1998; 32: 654-60.
20. Lob HE, Vinh A, Li L, Blinder Y, Offermanns S, Harrison DG. Role of vascular extracellular superoxide dismutase in hypertension. Hypertension 2011; 58: 232-9.
21. Yu Y, Xue BJ, Zhang ZH et al. Early interference with p44/42 mitogen-activated protein kinase signaling in hypothalamic paraventricular nucleus attenuates angiotensin II-Induced hypertension. Hypertension 2013; 61: 842-9.
22. King AJ, Fink GD. Chronic low-dose angiotensin II infusion increases venomotor tone by neurogenic mechanisms. Hypertension 2006; 48: 927-33.
23. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol. Rev. 1977; 57: 313-70.
24. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am. J. Physiol. 1992; 262: E763-78.
25. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998; 31: 10-4.
26. McKinley MJ, Albiston AL, Allen AM et al. The brain renin-angiotensin system: Location and physiological roles. Int. J. Biochem. Cell Biol. 2003; 35: 901-18.
27. Ramchandran R, Takezako T, Saad Y et al. Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proc. Natl Acad. Sci. USA 2006; 103: 19087-92.
28. Bonnet F, Cooper ME, Carey RM, Casley D, Cao Z. Vascular expression of angiotensin type 2 receptor in the adult rat: Influence of angiotensin II infusion. J. Hypertens. 2001; 19: 1075-81.
29. Ceravolo GS, Fernandes L, Munhoz CD et al. Angiotensin II chronic infusion induces B1 receptor expression in aorta of rats. Hypertension 2007; 50: 756-61.
30. Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, Gavras H. Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H1778-83.
31. 2 receptors: Functional relevance in cardiovascular disease. Pharmacol. Ther. 2008; 120: 292-316.
32. 2) release accompanying angiotensin conversion in rat mesenteric vasculature. Eur. J. Pharmacol. 1981; 70: 129-37.
33. Guyton AC, Coleman TG, Cowley AW Jr, Manning RD Jr, Norman RA Jr, Ferguson JD. A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ. Res. 1974; 35: 159-76.
34. Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, Cross RB. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am. J. Physiol. Renal Physiol. 1984; 246: F627-34.
35. Ong FS, Lin CX, Campbell DJ et al. Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity. Hypertension 2012; 59: 283-90.
36. Crowley SD, Song YS, Sprung G et al. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 2010; 55: 99-108.
37. Hercule HC, Tank J, Plehm R et al. Regulator of G protein signalling 2 ameliorates angiotensin II-induced hypertension in mice. Exp. Physiol. 2007; 92: 1014-22.
38. Braun-Menèndez E, Fasciolo JC. Mecanismo de la acciûn hipertensora de la sangre venosa del riòûn en isquemia incompleta aguda. Rev. Soc. Argent. Biol. 1939; 15: 401-10.
39. Slack BL, Ledingham JM. The influence of sodium intake on the pressor response to angiotensin II in the unanaesthetized rat. Clin. Sci. Mol. Med. 1976; 50: 285-91.
40. Osborn JW, Fink GD. Region-specific changes in sympathetic nerve activity in angiotensin II-salt hypertension in the rat. Exp. Physiol. 2010; 95: 61-8.
41. Crowley SD, Gurley SB, Oliverio MI et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 2005; 115: 1092-9.
42. Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension 2008; 51: 811-6.
43. McCubbin JW, Page IH. Renal inhibition of pressor responses to drugs. Circ. Res. 1954; 2: 35-40.
44. 1A receptor deletion on blood pressure and sodium excretion during altered dietary salt intake. Am. J. Physiol. Renal Physiol. 2002; 283: F447-53.
45. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 298: R1089-97.
46. Barhoumi T, Kasal DA, Li MW et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011; 57: 469-76.
47. Kvakan H, Kleinewietfeld M, Qadri F et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009; 119: 2904-12.
48. Lee DL, Sturgis LC, Labazi H et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H935-40.
49. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension. Role of renal vasoconstriction and Janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010; 56: 879-84.
50. Zhang W, Wang W, Yu H et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 2012; 59: 136-44.
51. Ma F, Li Y, Jia L et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS ONE 2010; 7: e35144.
52. Campbell DJ, Kladis A, Skinner SL, Whitworth JA. Characterization of angiotensin peptides in plasma of anephric man. J. Hypertens. 1991; 9: 265-74.
53. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991; 18: 763-73.
54. Alexiou T, Boon WM, Denton DA et al. Angiotensinogen and angiotensin converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J. Hypertens. 2005; 23: 945-54.
55. Hilgenfeldt U. Half-life of rat angiotensinogen: Influence of nephrectomy and lipopolysaccharide stimulation. Mol. Cell. Endocrinol. 1988; 56: 91-8.
56. Guilluy C, Bregeon J, Toumaniantz G et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 2010; 16: 183-90.
57. Stawski L, Han R, Bujor AM, Trojanowska M, Angiotensin II. induces skin fibrosis: A novel mouse model of dermal fibrosis. Arthritis Res. Ther. 2012; 14: R194.
58. Duchemin S, Belanger E, Wu R, Ferland G, Girouard H. Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol. Behav. 2013; 109: 63-8.
59. Zou LX, Hymel A, Imig JD, Navar LG. Renal accumulation of circulating angiotensin II in angiotensin II infused rats. Hypertension 1996; 27: 658-62.
60. Zou LX, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 1996; 28: 669-77.
61. 5-ANG II-infused rats. Am. J. Physiol. Renal Physiol. 2009; 296: F1067-71.
62. Gonzalez-Villalobos RA, Seth DM, Satou R et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am. J. Physiol. Renal Physiol. 2008; 295: F772-9.
63. Von Thun AM, Vari RC, El-Dahr SS, Navar LG. Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am. J. Physiol. Renal Physiol. 1994; 266: F120-8.
64. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 2004; 44: 223-9.
65. 1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am. J. Physiol. Renal Physiol. 2005; 289: F632-7.
66. Gonzalez-Villalobos RA, Satou R, Seth DM et al. Angiotensin-converting enzyme-derived angiotensin II formation during angiotensin II-induced hypertension. Hypertension 2009; 53: 351-5.
67. Kabour A, Henegar JR, Devineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc. Res. 1995; 29: 543-8.
68. Mizelle HL, Hall JE, Woods LL. Interactions between angiotensin II and renal nerves during chronic sodium deprivation. Am. J. Physiol. 1988; 255: F823-7.
69. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J. Clin. Endocrinol. Metab. 1983; 57: 764-70.
70. Koletsky RJ, Gordon MB, LeBoff MS et al. Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension. Clin. Sci. 1984; 66: 299-305.
71. Hannedouche T, Ikeni A, Marques LP et al. Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J. Cardiovasc. Pharmacol. 1992; 19(Suppl. 6): S25-7.
72. Brown RD, Hilliard LM, Head GA, Jones ES, Widdop RE, Denton KM. Sex differences in the pressor and tubuloglomerular feedback response to angiotensin II. Hypertension 2012; 59: 129-35.
73. Brown AJ, Clark SA, Lever AF. Slow rise and diurnal change of blood pressure with saralasin and angiotensin II in rats. Am. J. Physiol. 1983; 244: F84-8.
74. Page A, Reich H, Zhou J et al. Endothelial nitric oxide synthase gene/gender interactions and the renal hemodynamic response to angiotensin II. J. Am. Soc. Nephrol. 2005; 16: 3053-60.
75. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am. J. Physiol. 1998; 274: E867-76.
76. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 1996; 97: 2509-16.
77. Ishizaka N, Hongo M, Sakamoto A, Saito K, Furuta K, Koike K. Liver lipid content is reduced in rat given 7-day administration of angiotensin II. J. Renin Angiotensin Aldosterone Syst. 2011; 12: 462-8.
78. Rezk BM, Yoshida T, Semprun-Prieto L, Higashi Y, Sukhanov S, Delafontaine P. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 2012; 7: e30276.
79. Edgley AJ, Kett MM, Anderson WP. Evidence for renal vascular remodeling in angiotensin II-induced hypertension. J. Hypertens. 2003; 21: 1401-6.
80. Capers Q, Alexander RW, Lou P et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397-402.
81. Haudek SB, Cheng J, Du J et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2010; 49: 499-507.
82. Johnson RJ, Alpers CE, Yoshimura A et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-74.
83. Gratze P, Dechend R, Stocker C et al. Novel role for inhibitor of differentiation 2 in the genesis of angiotensin II-induced hypertension. Circulation 2008; 117: 2645-56.
84. Feng W, Chumley P, Hua P et al. Role of the transcription factor erythroblastosis virus E26 oncogen homolog-1 (ETS-1) as mediator of the renal proinflammatory and profibrotic effects of angiotensin II. Hypertension 2012; 60: 1226-33.
85. Gavras H, Lever AF, Brown JJ, Macadam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; 298: 19-22.
86. Hu L, Sealey JE, Chen R et al. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am. J. Hypertens. 2004; 17: 395-403.
87. Campbell DJ. The site of angiotensin production. J. Hypertens. 1985; 3: 199-207.
88. Campbell DJ, Angiotensin II. generation in vivo: Does it involve enzymes other than renin and angiotensin-converting enzyme? J. Renin Angiotensin Aldosterone Syst. 2012; 13: 314-6.
89. Matsusaka T, Niimura F, Shimizu A et al. Liver angiotensinogen is the primary source of renal angiotensin II. J. Am. Soc. Nephrol. 2012; 23: 1181-9.
90. Brand S, Amann K, Schupp N. Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts. J. Hypertens. 2013; 31: 333-44.
91. Fei DT, Scoggins BA, Tregear GW, Coghlan JP. Reduction of blood clearance rate of [Val5]angiotensin II by [Sar1, Ile8]angiotensin II in sheep. Life Sci. 1981; 29: 157-63.
92. Griffin SA, Brown WCB, MacPherson F et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17: 626-35.
93. Cao Z, Kelly DJ, Cox A et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000; 58: 2437-51.
94. 1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 2011; 13: 469-75.
95. Marvar PJ, Thabet SR, Guzik TJ et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ. Res. 2010; 107: 263-70.
96. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ. Res. 2004; 95: 210-6.
97. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J. Angiotensin II-induced hypertension is modulated by nuclear factor-κB in the paraventricular nucleus. Hypertension 2012; 59: 113-21.
98. Lob HE, Schultz D, Marvar PJ, Davisson RL, Harrison DG. Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension 2013; 61: 382-7.
99. Kharade SV, Sonkusare SK, Srivastava AK et al. The β3 subunit contributes to vascular calcium channel upregulation and hypertension in angiotensin II-infused C57BL/6 mice. Hypertension 2013; 61: 137-42.
100. + channels in arterial smooth muscle and contributes to hypertension. J. Biol. Chem. 2007; 282: 3231-40.
101. Widder JD, Guzik TJ, Mueller CF et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 762-8.
102. Wenzel P, Knorr M, Kossmann S et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124: 1370-81.
103. Hoch NE, Guzik TJ, Chen W et al. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 296: R208-16.
104. phox in rat angiotensin slow pressor response. Hypertension 2006; 47: 238-44.
105. Vinh A, Chen W, Blinder Y et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 2010; 122: 2529-37.
106. Madhur MS, Lob HE, McCann LA et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-7.
107. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: Evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2106-13.
108. Cao X, Peterson JR, Wang G et al. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain. Hypertension 2012; 59: 869-76.
109. Guan Y, Zhang Y, Wu J et al. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J. Clin. Invest. 2007; 117: 2496-505.
110. phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511-5.
111. phox is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice. Hypertension 2012; 59: 415-20.
112. Odenbach J, Wang X, Cooper S et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011; 57: 123-30.
113. Wang X, Chow FL, Oka T et al. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009; 119: 2480-9.